A case of refractory multiple myeloma

Ritesh Vekariya, Vishal Satadiya, Manish Bavaliya, Shyam Shah

Abstract


Multiple myeloma is a plasma cell cancer in which antibody-producing plasma cells grow in an uncontrolled and invasive way. The known incidence of multiple myeloma in India ranges from 0.5 to 1.2 per 100,000 & is a rare in India. It usually occurs in persons older than 55 years and the ratio of men: women is 3:2. Multiple myeloma affects the bones, immune system, kidneys and red blood cell count. We report a case of refractory multiple myeloma.


Keywords


M band, Pathologic fracture, Plasma cell cancer

Full Text:

PDF

References


Longo DL. Plasma cell disorders. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's Principles of Internal Medicine. 14th Ed. New York: McGraw Hill; 1998:712-3.

K├╝ppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341:1520-9.

Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81:219-23.

Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80:887-90.

Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986; 67:275-8.

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.

The EUROCARE-4 database on cancer survival in Europe. Available at http://www.eurocare.it/Results/tabid/79/Default.aspx#longsurv0002. Accessed 2 August 2012.